- Companies
- Digital Diagnostics
Digital Diagnostics Funding, Investors & Competitors
Digital Diagnostics has raised $168M across 6 funding rounds, most recently a $75M Series B in August 2022.
Last Digital Diagnostics funding round
$75M
Series B · Aug 2022
Cumulative funding Digital Diagnostics raised
$168M
across 6 funding rounds
Key investors in Digital Diagnostics
8VC
Optum Ventures
KKR
Alpha Edison
Kinderhook Industries
OSF Ventures
Heritage Provider Network
Cedar Pine
About Digital Diagnostics
Digital Diagnostics is an Iowa-headquartered artificial intelligence company that develops autonomous AI systems for clinical diagnostics. Its flagship product, IDx-DR, became the first FDA-cleared autonomous AI to detect diabetic retinopathy more than moderate severity in adults with diabetes during primary care visits. The platform employs patented biomarker detection to enable standalone decision-making without physician oversight. Previously known as IDx, the Coralville-based firm partners with federal regulators like the FDA and CMS for reimbursement coverage. It focuses on eye disease screening to expand access in underserved areas across the United States.
Founded
2010
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Digital Diagnostics Funding History
Digital Diagnostics has raised a total of $168M across 6 funding rounds.
Digital Diagnostics' first fundraising round was a $4M seed round in September 2013. The most recent completed round was a $75M Series B in August 2022.
Digital Diagnostics funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Aug 2022 | Series B | KKR (lead); Cedar Pine; OSF Ventures; 8VC; Gundersen Health System; Kinderhook Industries; University of Iowa; Edward-Elmhurst Health; Optum Ventures | $75M | Digital Diagnostics is an artificial intelligence diagnostic healthcare technology company based in Coralville, Iowa, focused on developing autonomous AI solutions for disease detection at the point-of-care. The company's flagship product, IDx-DR, is the first FDA De Novo authorized autonomous AI device in healthcare, designed to identify diabetic retinopathy and diabetic macular edema. IDx-DR has achieved FDA Breakthrough Device status and was distributed across 17 global markets and approximately 500 healthcare sites in the United States at the time of the funding announcement. On August 23, 2022, Digital Diagnostics closed a $75 million Series B funding round led by global investment firm KKR, with participation from Cedar Pine, Kinderhook, 8VC, Optum Ventures, OSF Ventures, Gundersen Health System, Edward-Elmhurst Health Venture Capital, and the University of Iowa. This round brought the company's total capital raised to more than $130 million. Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR, and Stephen Weiss, Managing Director of Cedar Pine, joined the company's board of directors as part of the investment. The Series B funding was intended to accelerate the product roadmap, expand the distribution network across four or more continents (with expectations to reach 1,500 to 2,000 healthcare sites by the end of 2023), and enhance sales and marketing efforts. The company positions its technology as a solution to healthcare access and affordability challenges, particularly in specialist care, by automating diagnostic decision-making and increasing health equity across diverse healthcare settings. |
| May 2022 | Undisclosed stage | - | $46M | Digital Diagnostics is a leading artificial intelligence diagnostic healthcare technology company developing autonomous and assistive AI for point-of-care diagnosis, aiming to democratize healthcare, close care gaps, and establish AI as a standard of care. The company became the first to receive FDA clearance in April 2018 for IDx-DR, an AI diagnostic platform that operates without physician input. It collaborates with patient advocacy groups, regulators, and ethics stakeholders to promote ethical AI adoption in healthcare. On August 23, 2022, Digital Diagnostics announced the closing of a $75 million Series B funding round led by KKR, with participation from Cedar Pine, Kinderhook, 8VC, Optum Ventures, OSF Ventures, Gundersen Health System, Edward-Elmhurst Health Venture Capital, and the University of Iowa. This brought total funding raised to more than $130 million. The proceeds are intended to accelerate the product roadmap, expand distribution, invest in sales and marketing, and scale the AI product pipeline for commercial growth in primary care, value-based care, and retail settings. The company reported accelerating commercial traction supporting the fundraise, with achievements including international expansion via an MOU with Saudi Arabia’s Ministry of Investment, a long-term strategic partnership with Baxter International to integrate IDx-DR (now LumineticsCore) with Welch Allyn RetinaVue 700 Imager, and a partnership with ArchWell Health for nationwide deployment. Ali Satvat from KKR and Stephen Weiss from Cedar Pine joined the board. |
| Sep 2018 | Series A | 8VC (lead); Heritage Provider Network; Alpha Edison; Optum Ventures | $33M | Digital Diagnostics (formerly IDx) is an AI diagnostics company developing autonomous AI systems for disease detection, starting with LumineticsCore (formerly IDx-DR), the first FDA-cleared autonomous AI for diabetic retinopathy screening at the point-of-care without clinician interpretation. The company secured $33 million in financing on September 26, 2018, led by 8VC, with participation from Optum Ventures, Alpha Edison, and Heritage Provider Network, to accelerate market adoption and develop additional AI diagnostics for macular degeneration, glaucoma, Alzheimer’s, cardiovascular disease, and stroke risk. Previously funded by angel investors since 2010, this round marked significant venture capital entry from strategic investors providing market expertise. The 2018 funding supported expansion of IDx-DR, targeting the 30 million U.S. diabetics needing annual retinopathy screening, enabling non-eye care providers to conduct tests during routine visits. The investment aligned with growing investor interest in AI-driven digital diagnostics, as seen in 2018's $8.1B digital health funding surge, with AI/ML diagnostics raising substantial amounts across deals. Digital Diagnostics continued growth post-2018, raising a $75 million Series B in August 2022 led by KKR, with participation from 8VC, Optum Ventures, and others, bringing total funding over $130 million to advance its AI product pipeline, sales, marketing, and distribution. One source lists a 2022 Series B post-money valuation of $286.24 million. The company focuses on making AI diagnosis standard-of-care to democratize healthcare and close care gaps. |
| Aug 2017 | Series A | - | $5M | - |
| Jan 2016 | Seed | - | $5M | - |
| Sep 2013 | Seed | - | $4M | - |
Who has invested in Digital Diagnostics?
11 investors have backed Digital Diagnostics across its funding rounds, including 8VC, Optum Ventures, KKR, Alpha Edison, Kinderhook Industries and OSF Ventures.
Lead investors include KKR and 8VC.
Digital Diagnostics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Sep 2018 | ||
| 2 | Participant | Sep 2018 | ||
| 1 | Participant | Sep 2018 | ||
| 1 | Participant | Aug 2022 | ||
| 1 | Lead | Aug 2022 | ||
| 1 | Participant | Aug 2022 | ||
| 1 | Participant | Aug 2022 | ||
| 1 | Participant | Sep 2018 | ||
| 1 | Participant | Aug 2022 | ||
This data is available for Pro users. Sign up to see all 11 Digital Diagnostics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Digital Diagnostics
Digital Diagnostics has acquired 1 company to date.
Last acquisition by Digital Diagnostics was on August 19th 2020. Digital Diagnostics acquired 3Derm Systems for undisclosed valuation.
Latest Acquisitions by Digital Diagnostics
| Description | 3Derm Systems is a creator of a skin imaging system enabling non-dermatologists to capture clinical-quality 3D images remotely via kiosks or home devices. The platform addresses the two million annual U.S. skin cancer cases by allowing dermatologists to triage lesions online, reducing in-office visits for low-risk patients and prioritizing urgent cases. Deployed at referral sites, it shortens wait times and lowers healthcare costs while maintaining local physician relationships. |
| HQ Country | |
| HQ City | - |
| Deal Date | 19 Aug 2020 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Digital Diagnostics acquisitions and their M&A valuation multiples. Start Free Trial | |
Digital Diagnostics Competitors
Digital Diagnostics competitors include listed companies like Tempus AI and SAP, and private ones like SiBionics, ConcertAI, Twin Health and K Health.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $717M | - | ||
| Publicly listed | $1.3B | ($131M) | $15B | 10.1x | ||
| Private | $200M | - | $1.9B | 9.5x | ||
| Private | - | - | $1.4B | - | ||
| Private | $52M | - | $900M | - | ||
| Publicly listed | $42B | $13B | $248B | 5.4x |
Digital Diagnostics Public Comps
Digital Diagnostics is still privately-owned, but its public comps include CrowdStrike, SAP, Salesforce, ServiceNow, Adobe, Datadog, Moody's, Natera, Workday and Agilent.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $4.8B | ($12M) | 51.4x | 44.5x | (19816.2x) | 151.0x | |||
| $42B | $13B | 5.8x | 5.4x | 18.4x | 17.1x | |||
| $42B | $13B | 5.5x | 5.2x | 17.8x | 12.2x | |||
| $13B | $2.6B | 11.1x | 9.6x | 57.2x | 25.0x | |||
| $24B | $9.3B | 4.3x | 3.9x | 10.9x | 8.2x | |||
| $3.4B | ($588K) | 23.6x | 19.4x | (137813.0x) | 77.6x | |||
| $7.7B | $3.8B | 11.2x | 10.6x | 22.5x | 20.1x | |||
| $2.3B | ($266M) | 22.5x | 19.0x | (195.0x) | (261.5x) | |||
This data is available for Pro users. Sign up to see all Digital Diagnostics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Digital Diagnostics
| When was Digital Diagnostics founded? | Digital Diagnostics was founded in 2010. |
| Where is Digital Diagnostics headquartered? | Digital Diagnostics is headquartered in Iowa City, IA, United States. |
| Is Digital Diagnostics publicly listed? | No, Digital Diagnostics is a private, VC-backed company. |
| How much funding has Digital Diagnostics raised? | Digital Diagnostics has raised $168M across 6 funding rounds. |
| What was Digital Diagnostics' last funding round? | Digital Diagnostics' last funding round was a $75M Series B in August 2022, led by KKR. |
| Who are Digital Diagnostics' investors? | Digital Diagnostics' investors include 8VC, Optum Ventures, Heritage Provider Network, Cedar Pine, KKR, OSF Ventures, Gundersen Health System, Alpha Edison, Kinderhook Industries, University of Iowa and 1 other. |
| Which companies are comparable to Digital Diagnostics? | Companies comparable to Digital Diagnostics include SiBionics, Tempus AI, ConcertAI, Twin Health, K Health and SAP. |
| How many companies has Digital Diagnostics acquired? | Digital Diagnostics has acquired 1 company, including 3Derm Systems. |
See companies similar to Digital Diagnostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




